학술논문
Circulating Mesenchymal Stromal Cells in Patients with Infantile Hemangioma: Evaluation of Their Functional Capacity and Gene Expression Profile.
Document Type
Article
Author
Abbà, Carlotta; Croce, Stefania; Valsecchi, Chiara; Lenta, Elisa; Campanelli, Rita; Codazzi, Alessia C.; Brazzelli, Valeria; Carolei, Adriana; Catarsi, Paolo; Acquafredda, Gloria; Apicella, Antonia; Caliogna, Laura; Berni, Micaela; Mannarino, Savina; Avanzini, Maria A.; Rosti, Vittorio; Massa, Margherita
Source
Subject
*GENE expression profiling
*ADIPOGENESIS
*STROMAL cells
*HEMANGIOMAS
*GENE expression
*DRUG target
*
*
*
*
*
Language
ISSN
2073-4409
Abstract
We previously published that in patients with infantile hemangioma (IH) at the onset (T0) colony forming unit-fibroblasts (CFU-Fs) are present in in vitro cultures from PB. Herein, we characterize these CFU-Fs and investigate their potential role in IH pathogenesis, before and after propranolol therapy. The CFU-F phenotype (by flow cytometry), their differentiation capacity and ability to support angiogenesis (by in vitro cultures) and their gene expression (by RT-PCR) were evaluated. We found that CFU-Fs are actual circulating MSCs (cMSCs). In patients at T0, cMSCs had reduced adipogenic potential, supported the formation of tube-like structures in vitro and showed either inflammatory (IL1β and ESM1) or angiogenic (F3) gene expression higher than that of cMSCs from CTRLs. In patients receiving one-year propranolol therapy, the cMSC differentiation in adipocytes improved, while their support in in vitro tube-like formation was lost; no difference was found between patient and CTRL cMSC gene expressions. In conclusion, in patients with IH at T0 the cMSC reduced adipogenic potential, their support in angiogenic activity and the inflammatory/angiogenic gene expression may fuel the tumor growth. One-year propranolol therapy modifies this picture, suggesting cMSCs as one of the drug targets. [ABSTRACT FROM AUTHOR]